320 related articles for article (PubMed ID: 15737005)
1. Designing equitable antiretroviral allocation strategies in resource-constrained countries.
Wilson DP; Blower SM
PLoS Med; 2005 Feb; 2(2):e50. PubMed ID: 15737005
[TBL] [Abstract][Full Text] [Related]
2. How far will we need to go to reach HIV-infected people in rural South Africa?
Wilson DP; Blower S
BMC Med; 2007 Jun; 5():16. PubMed ID: 17577418
[TBL] [Abstract][Full Text] [Related]
3. What strategies to boost production of affordable fixed-dose anti-retroviral drug combinations for children in the developing world?
Dionisio D; Gass R; McDermott P; Racalbuto V; Madeo M; Braghieri G; Crowley S; Pinheiro Edos S; Graaff P; Vasan A; Eksaengsri A; Moller H; Khanna AK; Kraisintu K; Juneja S; Nicolaou S; Sengupta A; Esperti F; Messeri D
Curr HIV Res; 2007 Mar; 5(2):155-87. PubMed ID: 17346132
[TBL] [Abstract][Full Text] [Related]
4. Designing an equitable strategy for allocating antiretroviral treatments.
Capron AM; Reis A
PLoS Med; 2005 Mar; 2(3):e69. PubMed ID: 15737013
[TBL] [Abstract][Full Text] [Related]
5. Predicting the epidemiological impact of antiretroviral allocation strategies in KwaZulu-Natal: the effect of the urban-rural divide.
Wilson DP; Kahn J; Blower SM
Proc Natl Acad Sci U S A; 2006 Sep; 103(38):14228-33. PubMed ID: 16968786
[TBL] [Abstract][Full Text] [Related]
6. Predicting the impact of antiretrovirals in resource-poor settings: preventing HIV infections whilst controlling drug resistance.
Blower S; Ma L; Farmer P; Koenig S
Curr Drug Targets Infect Disord; 2003 Dec; 3(4):345-53. PubMed ID: 14754434
[TBL] [Abstract][Full Text] [Related]
7. Introduction: the realities of antiretroviral therapy rollout: overcoming challenges to successful programmatic implementation.
Ojikutu B
J Infect Dis; 2007 Dec; 196 Suppl 3():S445-8. PubMed ID: 18181692
[TBL] [Abstract][Full Text] [Related]
8. Equity in access to ARV drugs in Malawi.
Ntata PR
SAHARA J; 2007 May; 4(1):564-74. PubMed ID: 18040535
[TBL] [Abstract][Full Text] [Related]
9. Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs.
Holmes CB; Coggin W; Jamieson D; Mihm H; Granich R; Savio P; Hope M; Ryan C; Moloney-Kitts M; Goosby EP; Dybul M
JAMA; 2010 Jul; 304(3):313-20. PubMed ID: 20639565
[TBL] [Abstract][Full Text] [Related]
10. Using geospatial modelling to optimize the rollout of antiretroviral-based pre-exposure HIV interventions in Sub-Saharan Africa.
Gerberry DJ; Wagner BG; Garcia-Lerma JG; Heneine W; Blower S
Nat Commun; 2014 Dec; 5():5454. PubMed ID: 25462707
[TBL] [Abstract][Full Text] [Related]
11. Separate goals, converging priorities: on the ethics of treatment as prevention.
Ostmann F; Saenz C
Dev World Bioeth; 2013 Aug; 13(2):57-62. PubMed ID: 23800304
[TBL] [Abstract][Full Text] [Related]
12. "The number of clients is increasing but the supplies are reducing": provider strategies for responding to chronic antiretroviral (ARV) medicines stock-outs in resource-limited settings: a qualitative study from Uganda.
Zakumumpa H; Kiweewa FM; Khuluza F; Kitutu FE
BMC Health Serv Res; 2019 May; 19(1):312. PubMed ID: 31092245
[TBL] [Abstract][Full Text] [Related]
13. The global pediatric antiretroviral market: analyses of product availability and utilization reveal challenges for development of pediatric formulations and HIV/AIDS treatment in children.
Waning B; Diedrichsen E; Jambert E; Bärnighausen T; Li Y; Pouw M; Moon S
BMC Pediatr; 2010 Oct; 10():74. PubMed ID: 20950492
[TBL] [Abstract][Full Text] [Related]
14. Ethical use of antiretroviral resources for HIV prevention in resource poor settings.
Rennie S
Dev World Bioeth; 2013 Aug; 13(2):79-86. PubMed ID: 23724978
[TBL] [Abstract][Full Text] [Related]
15. The past, present and future of HIV, AIDS and resource allocation.
Forsythe S; Stover J; Bollinger L
BMC Public Health; 2009 Nov; 9 Suppl 1(Suppl 1):S4. PubMed ID: 19922688
[TBL] [Abstract][Full Text] [Related]
16. Towards universal ARV access: achievements and challenges in Free State Province, South Africa.
Uebel KE; Timmerman V; Ingle SM; van Rensburg DH; Mollentze WF
S Afr Med J; 2010 Sep; 100(9):589-93. PubMed ID: 20822648
[TBL] [Abstract][Full Text] [Related]
17. How far should they walk? Increasing antiretroviral therapy access in a rural community in northern KwaZulu-Natal, South Africa.
Fredlund VG; Nash J
J Infect Dis; 2007 Dec; 196 Suppl 3():S469-73. PubMed ID: 18181696
[TBL] [Abstract][Full Text] [Related]
18. Antiretroviral treatment, government policy and economy of HIV/AIDS in Brazil: is it time for HIV cure in the country?
Benzaken AS; Pereira GFM; Costa L; Tanuri A; Santos AF; Soares MA
AIDS Res Ther; 2019 Aug; 16(1):19. PubMed ID: 31412889
[TBL] [Abstract][Full Text] [Related]
19. Access to antiretroviral treatment in developing countries: Which financing strategies are possible?
Beaulière A; Le Maux A; Trehin C; Perez F
Rev Epidemiol Sante Publique; 2010 Jun; 58(3):171-9. PubMed ID: 20430553
[TBL] [Abstract][Full Text] [Related]
20. Allocating scarce financial resources for HIV treatment: benchmarking prices of antiretroviral medicines in Latin America.
Wirtz VJ; Santa-Ana-Tellez Y; Trout CH; Kaplan WA
Health Policy Plan; 2012 Dec; 27(8):638-48. PubMed ID: 22367770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
